Navigation Links
Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
Date:12/14/2007

ith serious autoimmune and inflammatory conditions."

Alba will lead worldwide development operations through the end of Phase 2 clinical trials in Celiac disease. The companies will share responsibility for Phase 3 clinical trial execution and for the pursuit of additional indications such as Crohn's disease. This will leverage Shire's regulatory and clinical experience, as well as its commercial infrastructure.

Michael Yasick, Shire's Senior Vice President and Gastrointestinal Global Business Unit Leader added:

"We are excited about this opportunity for Shire to expand its GI franchise beyond mesalamine-related products such as Lialda(TM) / MEZAVANT XL(R). We look forward to working closely with Alba on the development of these new therapies."

Dr. Paterson also noted that, "this partnership is another step in Alba's evolution as a biopharmaceutical company and provides a significant validation of our barrier function technology platform, specifically applied to gastrointestinal disease. The partnership will also enhance our ability to provide solutions for other inflammatory and immune related diseases, both acute and chronic."

About AT-1001

AT-1001 is an inhibitor of barrier dysfunction that has been shown to block intestinal permeability and the genesis of some autoimmune diseases, both through the reduction of antigen presentation to the body's immune system and the inhibition of cytokine production. AT-1001 is orally formulated and is currently in Phase 2 studies for Celiac disease, a gastrointestinal autoimmune disease. INDs for oral AT-1001 in beta cell preservation (Type 1 Diabetes) and Crohn's disease have also been filed and cleared FDA review.

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to development and commercialization of disease modifying therapeutics to treat autoimmune and inflammatory di
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)...  The element of surprise has been a major ... without warning. Until now, epidemiologists had nothing to measure ... resulting in suboptimal responses to both the H1N1 pandemic ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 That ... virus gene structural changes have been found that invariably ...
(Date:11/21/2014)... England , Nov. 21, 2014   TRU-D SmartUVC ... will feature their superbug-killing UVC automated disinfection robot, TRU-D SmartUVC, ... this week from Nov. 23 to 26 at Stand 23. ... is the United Kingdom,s largest infection-related ... infection prevention societies to one of the leading events of ...
(Date:11/21/2014)... CA (PRWEB) November 20, 2014 Author ... Short Walk to the Other Side” published as ... “Award-Winning Finalist in the “Fiction: Short Story” category of ... Jeffrey Keen, President and CEO of USA Book News, ... mainstream and independent publishers, including Simon & Schuster, Penguin, ...
(Date:11/21/2014)... New York, NY (PRWEB) November 20, 2014 ... ) is now available as an open access journal ... cells with infrared fluorescent proteins to preserve photoresponsiveness in ... Two-color fluorescent in situ hybridization using chromogenic ... microfluidics chips for DNA, RNA, and protein electrophoresis , ...
Breaking Biology Technology:Viruses' Advantage of Surprise is Lost 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 2TRU-D SmartUVC to Showcase Superbug-Killing Robot at FIS 2014 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3
... SUNNYVALE, Calif., Aug. 5 Pharmacyclics, Inc. (Nasdaq: PCYC ... up to 22,500,000 shares of the Company,s common stock at a subscription ... on July 31, 2009. The Company increased the offering size on July ... to 22,500,000 shares. , , The subscription ...
... JEFFERSON, N.C., Aug. 5 Next Safety, Inc. (NSI) ... work in a pandemic environment. Next Safety is releasing for sale ... flu influenza A subtype H5N1. , , The ... became contagious. The Next Safety respirators are now being sold to ...
... , SANTA MONICA, Calif., Aug. 5 Cord ... stem cell preservation company ( http://www.cordblood-america.com ) ... families nationwide and internationally, said today it has retired $2.53M of ... in February and March of 2007 respectively, between CBAI and the ...
Cached Biology Technology:Pharmacyclics, Inc. Rights Offering Oversubscribed 2Pharmacyclics, Inc. Rights Offering Oversubscribed 3Next Safety Releases Advanced Respirator for Infectious Diseases 2Next Safety Releases Advanced Respirator for Infectious Diseases 3Cord Blood America Retires $2.53M Obligation 2Cord Blood America Retires $2.53M Obligation 3
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
(Date:11/10/2014)... appearing on U.S. store shelves in early 2010, and ... The small packets can be tossed into a washing ... or powder. The convenience, though, has come with risks ... at Nationwide Children,s Hospital found that from 2012 through ... children younger than 6 years of age swallowing, inhaling, ...
Breaking Biology News(10 mins):Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4Study finds laundry detergent pods, serious poisoning risk for children 2
... neuroscience research programme that spans basic science all the ... tertiary hospitals and medical schools, and a national organisation ... Singapore. These are some of the new initiatives ... Council (BMS IAC) at their annual meeting today. ...
... An international team of Australian and Israeli researchers has ... moonlight sex event on Earth., An ancient light-sensitive gene ... of Excellence for Coral Reef Studies (CoECRS) that appears ... spawning of corals across a third of a million ...
... method of constructing artificial plant chromosomes from small rings ... transport multiple genes at once into embryonic plants where ... passed on to the next generation -- a long-term ... In the October 19, 2007, issue of PLoS-Genetics, ...
Cached Biology News:Phase 2 of Singapore's Biomedical Sciences Initiative gains momentum for clinical research 2Phase 2 of Singapore's Biomedical Sciences Initiative gains momentum for clinical research 3Phase 2 of Singapore's Biomedical Sciences Initiative gains momentum for clinical research 4Phase 2 of Singapore's Biomedical Sciences Initiative gains momentum for clinical research 5Phase 2 of Singapore's Biomedical Sciences Initiative gains momentum for clinical research 6Key found to moonlight romance 2Key found to moonlight romance 3Transgenics transformed 2Transgenics transformed 3
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Request Info...
Request Info...
Non-Protein Peroxidase Stabilizer , 1 L...
Biology Products: